Keloid Scarring: New Treatments Ahead

Actas Dermo-Sifiliograficas

Volumn 100, Issue SUPPL. 2, 2009, Pages 75-83

  Mrowietz, Ulrich ^a   Seifert, Oliver ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

imatinib mesylate; interleukin 10; keloid; molecular mechanisms; physiopathology; TGF 3; treatment

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; FLUOROURACIL; GAMMA INTERFERON; HYDROCORTISONE ACETATE; IMIQUIMOD; MEPREDNISONE; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; VERAPAMIL;

ARGON LASER; ARTICLE; CARBON DIOXIDE LASER; CLINICAL TRIAL; CRYOTHERAPY; FOLLOW UP; HUMAN; KELOID; NEODYMIUM LASER; PULSED DYE LASER; RADIATION DOSE;

FORECASTING; HUMANS; KELOID;

EID: 77049105460     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)73382-4     Document Type: Article

References (81)

1. Ladin D. The art and science of wound care. Plast Reconstr Surg 96 (1995) 748
2. Breasted J.H. The Edwin Smith surgical papyrus. Hieroglyphic translation and commentary (1930), University of Chicago Press, Chicago
3. Alibert J.L.M. Description des maladies de la peau observées a l'hôpital Saint-Louis et exposition des meilleures methodes suives pour leur traitment (1806), Barrois l'aine et fils, Paris p. 113
4. Tuan T.L., and Nichter L.S. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 4 (1998) 19-24
5. Tredget E.E., Nedelec B., Scott P.G., and Ghahary A. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am 77 (1997) 701-730
6. Pitche P. What is true in "spontaneous" keloids?. Ann Dermatol Venereol 133 (2006) 501
7. McGrouther D.A. Hypertrophic or keloid scars?. Eye 8 Pt 2 (1994) 200-203
8. Bayat A., Arscott G., Ollier W.E., Ferguson M.W., and Mc Grouther D.A. Description of site-specific morphology of keloid phenotypes in an Afrocaribbean population. Br J Plast Surg 57 (2004) 122-133
9. Prado A.S., and Fontbona M. A 1.8-kg keloid of the arm. Plast Reconstr Surg 117 (2006) 335-336
10. Brissett A.E., and Sherris D.A. Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg 17 (2001) 263-272
11. Lindsey W.H., and Davis P.T. Facial keloids. A 15-year experience. Arch Otolaryngol Head Neck Surg 123 (1997) 397-400
12. Cosman B., Crikelair F., Ju M.C., Gaulin J.C., and Lattes R. The surgical treatment of keloids. Plast Reconstr Surg 27 (1961) 335-345
13. Schierle H.P., Scholz D., and Lemperle G. Elevated levels of testosterone receptors in keloid tissue: an experimental investigation. Plast Reconstr Surg 100 (1997) 390-395
14. Oluwasanmi J.O. Keloids in the African. Clin Plast Surg 1 (1974) 179-195
15. Bloom D. Heredity of keloids. N Y State Med J 56 (1956) 511-519
16. Bock O., Schmid-Ott G., Malewski P., and Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 297 (2006) 433-438
17. Mustoe T.A., Cooter R.D., Gold M.H., Hobbs F.D., Ramelet A.A., Shakespeare P.G., et al. International clinical recommendations on scar management. Plast Reconstr Surg 110 (2002) 560-571
18. Schaffer M.R., Efron P.A., Thornton F.J., Klingel K., Gross S.S., and Barbul A. Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol 158 (1997) 2375-2381
19. Kauh Y.C., Rouda S., Mondragon G., Tokarek R., diLeonardo M., Tuan R.S., et al. Major suppression of pro-alpha1(I) type I collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamcinolone acetonide. J Am Acad Dermatol 37 (1997) 586-589
20. Jalali M., and Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon 5 (2007) 175-180
21. Darzi M.A., Chowdri N.A., Kaul S.K., and Khan M. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg 45 (1992) 374-379
22. Layton A.M., Yip J., and Cunliffe W.J. A comparison of intralesional triamcinolone and cryosurgery in the treatment of acne keloids. Br J Dermatol 130 (1994) 498-501
23. Yosipovitch G., Widijanti Sugeng M., Goon A., Chan Y.H., and Goh C.L. A comparison of the combined effect of cryotherapy and corticosteroid injections versus corticosteroids and cryotherapy alone on keloids: a controlled study. J Dermatolog Treat 12 (2001) 87-90
24. Manuskiatti W., and Fitzpatrick R.E. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 138 (2002) 1149-1155
25. Durani P., and Bayat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg 61 (2008) 4-17
26. Mustoe T.A. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg 32 (2008) 82-92
27. Berman B., Pérez O.A., Konda S., Kohut B.E., Viera M.H., Delgado S., et al. A review of the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol Surg 33 (2007) 1291-1302
28. O'Brien L., and Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev (2006) CD003826
29. Niessen F.B., Spauwen P.H., Schalkwijk J., and Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 104 (1999) 1435-1458
30. Ernst K., and Hundeiker M. Results of cryosurgery in 394 pa tients with hypertrophic scars and keloids. Hautarzt 46 (1995) 462-466
31. Shepherd J.P., and Dawber R.P. The response of keloid scars to cryosurgery. Plast Reconstr Surg 70 (1982) 677-682
32. Alster T.S., and Williams C.M. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 345 (1995) 1198-1200
33. Dierickx C., Goldman M.P., and Fitzpatrick R.E. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 95 (1995) 84-90
34. Kumar K., Kapoor B.S., Rai P., and Shukla H.S. In-situ irradiation of keloid scars with Nd:YAG laser. J Wound Care 9 (2000) 213-215
35. Kantor G.R., Wheeland R.G., Bailin P.L., Walker N.P., and Ratz J.L. Treatment of earlobe keloids with carbon dioxide laser excision: a report of 16 cases. J Dermatol Surg Oncol 11 (1985) 1063-1067
36. Klumpar D.I., Murray J.C., and Anscher M. Keloids treated with excision followed by radiation therapy. J Am Acad Dermatol 31 (1994) 225-231
37. Ogawa R., Mitsuhashi K., Hyakusoku H., and Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg 111 (2003) 547-553
38. Ragoowansi R., Cornes P.G., Moss A.L., and Glees J.P. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast Reconstr Surg 111 (2003) 1853-1859
39. Panizzon R.G. Dermatologic radiotherapy. Hautarzt 58 (2007) 701-710
40. Sclafani A.P., Gordon L., Chadha M., and Romo III T. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Dermatol Surg 22 (1996) 569-574
41. Maarouf M., Schleicher U., Schmachtenberg A., and Ammon J. Radiotherapy in the management of keloids. Clinical experience with electron beam irradiation and comparison with X-ray therapy. Strahlenther Onkol 178 (2002) 330-335
42. Caccialanza M., Piccinno R., and Schiera A. Postoperative radiotherapy of keloids: a twenty-year experience. Eur J Dermatol 12 (2002) 58-62
43. Fraunholz I.B., Gerstenhauer A., and Bottcher H.D. Results of postoperative (90)Sr radiotherapy of keloids in view of patients' subjective assessment. Strahlenther Onkol 181 (2005) 724-729
44. Guix B., Henríquez I., Andrés A., Finestres F., Tello J.I., and Martínez A. Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol Biol Phys 50 (2001) 167-172
45. Kovalic J.J., and Pérez C.A. Radiation therapy following keloidectomy: a 20-year experience. Int J Radiat Oncol Biol Phys 17 (1989) 77-80
46. Doornbos J.F., Stoffel T.J., Hass A.C., Hussey D.H., Vigliotti A.P., Wen B.C., et al. The role of kilovoltage irradiation in the treatment of keloids. Int J Radiat Oncol Biol Phys 18 (1990) 833-839
47. Brent B. The role of pressure therapy in management of earlobe keloids: preliminary report of a controlled study. Ann Plast Surg 1 (1978) 579-581
48. Rauscher G.E., and Kolmer W.L. Treatment of recurrent earlobe keloids. Cutis 37 (1986) 67-68
49. Berman B., and Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 47 (2002) S209-S211
50. Martín-García R.F., and Busquets A.C. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg 31 (2005) 1394-1398
51. Patel P.J., and Skinner Jr. R.B. Experience with keloids after excision and application of 5% imiquimod cream. Dermatol Surg 32 (2006) 462
52. Cacao F.M., Tanaka V., and Messina M.C. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg 35 (2009) 629-633
53. Blumenkranz M., Hernández E., Ophir A., and Norton E.W. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91 (1984) 122-130
54. de Waard J.W., de Man B.M., Wobbes T., van der Linden C.J., and Hendriks T. Inhibition of fibroblast collagen synthesis and proliferation by levamisole and 5-fluorouracil. Eur J Cancer 34 (1998) 162-167
55. Jiménez S.A., Freundlich B., and Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74 (1984) 1112-1116
56. Berman B., and Duncan M.R. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 21 (1989) 694-702
57. al-Khawajah M.M. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol 35 (1996) 515-517
58. Larrabee Jr. W.F., East C.A., Jaffe H.S., Stephenson C., and Peterson K.E. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg 116 (1990) 1159-1162
59. Copcu E., Sivrioglu N., and Oztan Y. Combination of surgery and intralesional verapamil injection in the treatment of the keloid. J Burn Care Rehabil 25 (2004) 1-7
60. Rehman J., Benet A., and Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 51 (1998) 620-626
61. Varga J., and Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117 (2007) 557-567
62. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 342 (2000) 1350-1358
63. Shah M., Foreman D.M., and Ferguson M.W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339 (1992) 213-214
64. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56 (2007) 323-333
65. Mead A.L., Wong T.T., Cordeiro M.F., Anderson I.K., and Khaw P.T. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 44 (2003) 3394-3401
66. Gary-Bobo M., Nirde P., Jeanjean A., Morere A., and García M. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem 14 (2007) 2945-2953
67. Santiago B., Gutiérrez-Canas I., Dotor J., Palao G., Lasarte J.J., Ruiz J., et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 125 (2005) 450-455
68. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96 (1999) 319-328
69. Horan G.S., Wood S., Ona V., Li D.J., Lukashev M.E., Weinreb P.H., et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 177 (2008) 56-65
70. Puthawala K., Hadjiangelis N., Jacoby S.C., Bayongan E., Zhao Z., Yang Z., et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 177 (2008) 82-90
71. Ishida W., Mori Y., Lakos G., Sun L., Shan F., Bowes S., et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 126 (2006) 1733-1744
72. Mori Y., Ishida W., Bhattacharyya S., Li Y., Platanias L.C., and Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 50 (2004) 4008-4021
73. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
74. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56 (2007) 311-322
75. Bock O., Yu H., Zitron S., Bayat A., Ferguson M.W., and Mrowietz U. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta Derm Venereol 85 (2005) 216-220
76. Shah M., Foreman D.M., and Ferguson M.W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108 Pt 3 (1995) 985-1002
77. Ferguson M.W., Duncan J., Bond J., Bush J., Durani P., So K., et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 373 (2009) 1264-1274
78. Ghazizadeh M. Essential role of IL-6 signaling pathway in keloid pathogenesis. J Nippon Med Sch 74 (2007) 11-22
79. Liechty K.W., Kim H.B., Adzick N.S., and Crombleholme T.M. Fetal wound repair results in scar formation in interleukin10-deficient mice in a syngeneic murine model of scarless fetal wound repair. J Pediatr Surg 35 (2000) 866-872
80. Peranteau W.H., Zhang L., Muvarak N., Badillo A.T., Radu A., Zoltick P.W., et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol 128 (2008) 1852-1860
81. Zhang G.Y., Yi C.G., Li X., Zheng Y., Niu Z.G., Xia W., et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res 300 (2008) 177-184